Movatterモバイル変換

[0]ホーム

Jump to content

Tucotuzumab celmoleukin

Italiano

Edit links

From Wikipedia, the free encyclopedia

Monoclonal antibody drug

Pharmaceutical compound

Tucotuzumab celmoleukin
Monoclonal antibody
Type	Whole antibody
Source	Humanized (frommouse)
Target	EpCAM
Clinical data
Other names	EMD 273066
ATC code	none
Identifiers
CAS Number	339986-90-2^Y
ChemSpider	none
UNII	4ON7FF680U
KEGG	D09027^Y
Chemical and physical data
Formula	C₇₈₁₂H₁₂₁₂₄N₂₀₄₄O₂₄₀₈S₆₀
Molar mass	175130.42 g·mol⁻¹
(verify)

Tucotuzumab celmoleukin is an anti-cancer drug. It is afusion protein of ahumanized monoclonal antibody (tucotuzumab) and aninterleukin-2 (celmoleukin).^[1]^[2]^[3]

This drug was developed byEMD Pharmaceuticals.

References

[edit]

^Statement On A Nonproprietary Name Adopted By The Usan Council - Tucotuzumab Celmoleukin,American Medical Association.
^Clinical trial numberNCT00016237 atClinicalTrials.gov
^"Definition of tucotuzumab celmoleukin".National Cancer Institute.

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab^§ Amivantamab Ascrinvacumab^§ Balstilimab^† Botensilimab Cixutumumab^§ Conatumumab^§ Cosibelimab Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin Enoticumab^§ Figitumumab^§ Flanvotumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Linvoseltamab Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Nivolumab^# (+hyaluronidase,+relatlimab) Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Sugemalimab Tarextumab^§ Tisotumab vedotin Teprotumumab^† Tovetumab^§ Vantictumab^§ Votumumab^§ Zalutumumab^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ecromeximab^§ Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab^# Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab^§ Alemtuzumab Atezolizumab (+hyaluronidase) Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Datopotamab deruxtecan Denintuzumab mafodotin^§ Elotuzumab Emactuzumab Emibetuzumab^§ Enoblituzumab^§ Epcoritamab Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab^§ Inotuzumab ozogamicin Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Naxitamab Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Odronextamab Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pembrolizumab^# (+berahyaluronidase alfa) Penpulimab Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan Sibrotuzumab^§ Simtuzumab^§ Sofituzumab vedotin^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab^# (+deruxtecan /+emtansine) Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§ Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab^§
Chimeric + humanized	Depatuxizumab mafodotin^† Duvortuxizumab Ontuxizumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Interleukin receptor modulators

IL-1

Decoy receptors:Rilonacept (IL-1 Trap)

IL-2

IL-3

IL-4

Antagonists:Pitrakinra

Antibodies:Dupilumab
Pascolizumab

IL-5

Agonists:Interleukin 5

Antagonists:YM-90709

Antisense oligonucleotides:TPI ASM8

IL-6

Agonists:Atexakin alfa
Interleukin 6

IL-7

Agonists:Interleukin 7

IL-8

See CXCR1 (IL-8Rα) and CXCR2 (IL-8Rβ)here instead.

IL-9

Agonists:Interleukin 9

Antibodies:Enokizumab

IL-10

Agonists:Ilodecakin
Interleukin 10 (CSIF)

IL-11

Agonists:Interleukin 11 (AGIF)
Oprelvekin

IL-12

Agonists:Edodekin alfa
Interleukin 12

Antibodies:Briakinumab
Ustekinumab

IL-13

IL-15

Agonists:ALT-803
Interleukin 15

IL-17

Agonists:Interleukin 17 (A,B,C,D,E (interleukin 25),F)

IL-18

Binding proteins:IL18BP

IL-20

Antibodies:Fletikumab (against IL-20)

IL-21

Agonists:Denenicokin
Interleukin 21

Antibodies:NNC0114-0005
NNC0114-0006

IL-22

Agonists:Interleukin 22

Antibodies:Fezakinumab (against IL-22)

IL-23

Agonists:Interleukin 23 (SGRF)

IL-27

Agonists:Interleukin 27 (interleukin 30)

IL-28

IL-31

Agonists:Interleukin 31

IL1RL1

Agonists:Interleukin 33

IL1RL2

Agonists:Interleukin 36 (α,β,γ)
Interleukin 38

Antagonists:IL-36RA

Others

JAK	Seehere instead.
Others	Interleukin 14 (taxilin alpha, HMW-BCGF) Interleukin 16 (signals throughCD4) Interleukin 24 (signals throughIL-22Rα1/IL-20Rβ heterodimer) Interleukin 26 (signals throughIL-20Rα/IL-10Rβ heterodimer) Interleukin 32 Interleukin 34 (signals throughM-CSFR/CSF1R) Interleukin 35 Unsorted:Efavaleukin alfa Efineptakin alfa

Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it.

Thisantineoplastic orimmunomodulatory drug article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Tucotuzumab_celmoleukin&oldid=1289844214"

Categories:

Hidden categories:

[8]ページ先頭